Patents by Inventor Takaki Habuchi

Takaki Habuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleic acid compound and oligonucleotide
    Patent number: 11905308
    Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.
    Type: Grant
    Filed: February 9, 2022
    Date of Patent: February 20, 2024
    Assignee: OSAKA UNIVERSITY
    Inventors: Satoshi Obika, Kosuke Ito, Takaki Habuchi, Masahiko Horiba
  • 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME
    Publication number: 20220372060
    Abstract: Disclosed are a 5?-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The 5?-modified nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The 5?-modified nucleoside also has excellent industrial productivity because a diastereomer separation step is not involved in the production process thereof.
    Type: Application
    Filed: January 31, 2020
    Publication date: November 24, 2022
    Inventors: Satoshi OBIKA, Takao YAMAGUCHI, Takaki HABUCHI, Go KATO, Takao INOUE, Tokuyuki YOSHIDA, Takaya SUGIURA
  • NUCLEIC ACID COMPOUND AND OLIGONUCLEOTIDE
    Publication number: 20220169671
    Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.
    Type: Application
    Filed: February 9, 2022
    Publication date: June 2, 2022
    Applicant: Osaka University
    Inventors: Satoshi OBIKA, Kosuke ITO, Takaki HABUCHI, Masahiko HORIBA
  • 5'-MODIFIED NUCLEOSIDE AND NUCLEOTIDE USING SAME
    Publication number: 20220127300
    Abstract: Disclosed are a 5?-modified nucleoside and a nucleotide using the same. The nucleoside of the present invention is represented by the formula (I) below. The 5?-modified nucleoside of the present invention is usable as a substitute for a phosphorothioate-modified nucleic acid, which has a risk of, for example, accumulation in a specific organ. The 5?-modified nucleoside also has excellent industrial productivity because a diastereomer separation step is not involved in the production process thereof.
    Type: Application
    Filed: February 10, 2020
    Publication date: April 28, 2022
    Inventors: Satoshi OBIKA, Takao YAMAGUCHI, Takaki HABUCHI, Go KATO, Takao INOUE, Tokuyuki YOSHIDA, Md Ariful ISLAM
  • Nucleic acid compound and oligonucleotide
    Patent number: 11286275
    Abstract: The present invention aims to provide a nucleic acid compound that hardly forms non-Watson-Crick base pairs, and an oligonucleotide containing the nucleic acid compound and showing reduced non-specific binding with nucleic acids other than the target nucleic acid. The nucleic acid compound according to the present invention is characterized in that the 2-position carbonyl group of the pyrimidine base is functionally converted (X1 and X2 are each independently S or Se), and that the 2?-position and the 4?-position are bridged in a particular structure. The oligonucleotide according to the present invention is characterized in that at least one of thymidine and uridine is the nucleic acid compound.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: March 29, 2022
    Assignee: Osaka University
    Inventors: Satoshi Obika, Kosuke Ito, Takaki Habuchi, Masahiko Horiba